Purpose: Adoption of hypofractionated whole breast irradiation (HWBI) for patients with early-stage, biologically high-risk breast cancer remains relatively low. We compared clinical outcomes of conventionally fractionated whole breast irradiation (CWBI) versus moderate HWBI in this patient population.
Methods And Materials: We queried a prospectively maintained database for patients with early-stage (T1-2, N0, M0) breast cancer who received whole breast irradiation with either CWBI or moderate HWBI at a single institution. We included only patients with biologically high-risk tumors (defined as either estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 negative, human epidermal growth factor receptor 2 amplified, and/or patients with a high-risk multigene assay) who received systemic chemotherapy. Inverse probability of treatment weighting was used to compare treatment cohorts and to estimate 5-year time to event endpoints. Hazard ratios (HR) and 95% confidence interval (CI) were determined based on Cox proportional hazards model.
Results: We identified 300 patients, of whom 171 received CWBI and 129 received HWBI. There was a statistically significant difference in median age at diagnosis, 59 years for CWBI versus 63 years for HWBI (P = .004), and in median follow-up time, 97 months for CWBI versus 55 months for HWBI (P < .001). After accounting for differences in patient and tumor characteristics with inverse probability of treatment weighting, we found similar 5-year freedom from local recurrence (HR, 0.76; 95% CI, 0.14-4.1), freedom from regional recurrence (HR, 3.395% CI 0.15-69), freedom from distant metastasis (HR 3.9, 95% CI 0.86-17), and disease-free survival (HR 0.84; 95% CI, 0.3-2.4), between those treated with CWBI and those treated with HWBI. Results were similar among each of the 3 high-risk subtypes.
Conclusions: Our data support the use of moderate HWBI in patients with early-stage, biologically high-risk breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.prro.2022.06.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The status of serum 25(OH)D levels is related to breast cancer.
Cancer Treat Res Commun
January 2025
Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
Aim: Breast cancer is the second most common cancer among women and the leading cause of cancer-related mortality in this population. Numerous factors have been identified as either risk factors or protective factors for breast cancer. However, the role of Vitamin D (Vit.
View Article and Find Full Text PDFNext-Generation Photosensitizers: Cyanine-Carborane Salts for Superior Photodynamic Therapy of Metastatic Cancer.
Angew Chem Int Ed Engl
January 2025
Michigan State University, Biochemistry and Molecular Biology, Biochemistry Building, 603 Wilson Rd, Lunt Lab, 48824, 48824, East Lansing, UNITED STATES OF AMERICA.
Photodynamic therapy (PDT) has emerged as a promising targeted treatment for cancer. However, current PDT is limited by low tissue penetration, insufficient phototoxicity (toxicity with light irradiation), and undesirable cytotoxicity (toxicity without light irradiation). Here, we report the discovery of cyanine-carborane salts as potent photosensitizers (PSs) that harness the near-infrared (NIR) absorbing [cyanine+] with the inertness of [carborane-].
View Article and Find Full Text PDFCurcumin-coated iron oxide nanoparticles for photodynamic therapy of breast cancer.
Photochem Photobiol Sci
January 2025
Nanosensors Laboratory, Research & Development Institute, University of Vale do Paraíba, Av. Shishima Hifumi, 2911, Urbanova, São José dos Campos, São Paulo, Brazil.
Breast cancer is the deadliest cancer among women and its treatment using traditional methods leads the patient to experience adverse effects. However, photodynamic therapy (PDT) is a non-invasive therapy modality that works through a photosensitizing agent, which treating activated by a suitable light source, releases reactive oxygen species capable of treating cancer. Furthermore, recent research indicates that combining PDT and nanoparticles can enhance therapeutic effects.
View Article and Find Full Text PDFPeptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.
Adv Sci (Weinh)
January 2025
Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I.
View Article and Find Full Text PDFDual-layer detector spectral computed tomography quantitative parameters for predicting pathological complete remission after neoadjuvant treatment of breast cancer.
Quant Imaging Med Surg
January 2025
Department of Radiation Oncology Physics & Technology, Cancer Hospital of Shandong First Medical University, Jinan, China.
Background: Breast cancer (BC) is a common cancer among women worldwide, and although the use of neoadjuvant therapy (NAT) for BC has become more widespread, there is no standardized prediction of the efficacy of NAT for BC. This study aimed to evaluate the value of quantitative parameters of dual-layer detector spectral computed tomography (DLCT) in predicting whether BC patients can achieve pathological complete response (pCR) after NAT.
Methods: Patients who were first diagnosed with BC in Shandong Cancer Hospital and Institute and received only NAT before surgery were selected for participation in this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!